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Abstract in English 
In the drug development process the ADME profile and the toxicity of a drug candidate are of 
major importance for its success. Here the ATP-dependant efflux pump P-glycoprotein (P-gp) 
plays a key role as it is expressed in biological barriers, like intestinal epithelium, blood brain 
barrier, proximal renal tubular cells and hepatocytes. The protein transports xenobiotic 
compounds with a broad substrate and inhibitor specificity out of the cell. Consequently, 
predictive in silico models for human P-gp activity are valuable tools in drug development.  
However, at an early stage of drug development essential data is acquired in animal studies 
and consequently it is of utmost importance that drug candidates show a preferable 
pharmacokinetic and toxicity profile in animals. Thus next to existing predictive in silico 
models against human P-gp activity, predictive in silico models against rat and mouse would 
enable the avoidance of an early attrition in the following preclinical phase of animal in vivo 
studies. .  
 
Recently a crystal structure of mouse P-gp was established and provides new possibilities for 
structure-based drug design approaches. The high sequence identity between rat and mouse P-
gp (92%) and the importance of rats in animal ADME models motivated us to create a 
homology model of rat P-gp taking the crystallized mouse P-gp as a template. A multiple 
sequence alignment was performed using ClustalW2 and the resulting alignment was then 
used within MODELLER for model generation.  
 
Subsequently the docking software GOLD was used to dock 6 rat P-gp inhibitors with known 
IC50 values into the rat homology model. Docking poses were analyzed and showed frequent 
interactions between the ligand poses and F70 (TM helix 1) and F335 (TM helix 6). Also 
residue T306 (TM helix 5) was involved, whose human analogue T307 was (experimentally) 
shown to be important in ligand interactions. The predictive power of the model could be 
validated by comparing the rankings resulting from the scoring function GOLDScore and the 
experimentally determined activity: the docking was able to correctly assign the ranking for 
all but one of the experimentally tested compounds (only ranks 3 and 4 were switched).  
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Zusammenfassung 
Während des Drug Development Prozesses sind ADME und Toxizität eines Wirkstoff 
Kandidaten ausschlaggebend für seinen Erfolg. Hier spielt die ATP-abhängige Efflux Pumpe 
P-Glykoprotein (P-gp), die im Darmepithel, in der Blut-Hirn-Schranke, in proximalen 
Tubuluszellen der Niere und in Hepatozyten exprimiert wird, eine entscheidende Rolle. Das 
Protein transportiert xenobiotische Substanzen mit einem breiten Substrat und Inhibitor Profil 
aus der Zelle. Folglich sind vorhersagende in silico Modelle für das humane P-gp ein 
wertvolles Instrument im Drug Development. Allerdings werden in einem frühen Stadium des 
Drug Developments essentielle Daten in Tierstudien gewonnen, deswegen ist es besonders 
wichtig, dass ein Wirkstoffkandidat ein günstiges pharmakokinetisches Profil im Tiermodell 
zeigt. Daher könnten, abgesehen von den bestehenden in silico Vorhersagemodellen für das 
menschliche P-gp, in silico Vorhersagemodelle für das Ratten und Maus P-gp die 
Abbruchrate in den in vivo Tierstudien während der nächsten präklinischen Phase senken.   
 
Kürzlich wurde die Kristallstruktur des Maus P-gp aufgeklärt und schafft somit neue 
Möglichkeiten für strukturbasiertes Wirkstoffdesign. Die hohe Sequenzidentität zwischen 
Ratte und Maus (92%) und die Bedeutung von Ratten in ADME Tiermodellen motivierte uns 
ein Homologie Modell der Ratte zu entwickeln, als dessen Vorlage die Kristallstruktur des 
Maus P-gp herangezogen wurde. Ein multiples Sequenzalignment wurde mit ClustalW2 
durchgeführt und das resultierende Alignement wurde für die Modellberechnung mit 
MODELLER eingesetzt.  
 
Anschließend wurden 6 P-gp Inhibitoren der Ratte  mit bekannten IC50 Werten mit Hilfe der 
Docking Software GOLD in das Ratten Homologie Modell gedockt. Die Analyse der Docking 
Posen zeigte häufige Interaktionen zwischen den Aminosäuren F70 (TM Helix 1) und F335 
(TM Helix 6). Auch Aminosäure T306 war an Interaktionen beteiligt, dessen humanes 
Analogon T307 (experimentell) nachweislich bei Ligandeninteraktionen von Bedeutung ist. 
Die Vorhersagekraft des Modells konnte durch Vergleich der Ranking Ergebnisse, die mit 
Hilfe von GOLDScore berechnet wurden, mit den experimentell getesteten Aktivitäten 
validiert werden: das Docken war in der Lage alle außer einer experimentell getesteten 
Verbindungen richtig zuzuordnen (nur Nummer 3 und 4 waren vertauscht).  
 
 
 
  
4 
 
  
5 Introduction 
I. Introduction 
 
 
A. Drug Development 
 
The drug development process takes about 10-15 years to develop a new drug from the 
discovery until the chance of treating patients. The costs of research and development of each 
successful drug are in average approximately 800 million to 1 billion U.S. dollars. The 
failures are included in that amount: for every 5000-10000 compounds which enter the 
research and development pipeline in the end only one is approved [Figure 1] [1-4]. 
 
 
Figure 1 – Depiction of the drug development process, figure taken from [3]. 
 
 
Identify Disease 
Before starting the discovery of a new potential drug, the focus lies on understanding the 
underlying disease and the cause of the condition for finding the best possible treatment. It is 
of great importance to understand how the genes are altered, how that affects the proteins they 
encode and how those proteins interact with each other in living cells, how those affected 
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cells change the specific tissue they are in, and finally how the disease affects the entire 
patient. This knowledge is the fundament for an accurate treatment of the disease. 
However, the research and the development of new drugs often end in nowhere. Even if your 
research is successful there are still many years of work and possible dead ends ahead before 
the understanding of a disease can be turned into a new treatment.  
 
Target Identification 
The next step after understanding the disease and its cause is to choose the target for a 
potential new drug. A target most often is a single macromolecule, e.g. a gene or protein, 
which plays a role in the explored disease. At this point of research it plays an important role 
to select such a target that is able to interact and to be modified by a new drug molecule 
(drugable target).  
 
Target Validation 
Once a potential target is chosen it has to be shown that it is involved in the disease and can 
be accessed and also affected by a drug. This step of research is essential to avoid promising 
looking drug candidates to finish in dead ends.  
 
Drug Discovery 
After having understood the disease and having found a validated target the search for a drug 
starts. The focus lies on a molecule, which can also be called “lead compound” that is able to 
interact with the target in a way to modify the course of the disease. If this search turns out to 
be successful in many years and after a lot of testing the lead compound could become a new 
drug.  
There are different ways to determine the lead compound: 
1. From nature: In former times there were no high tech methods to find new compounds 
in the way we discover them today. In the lack of these techniques nature very often 
delivered templates for new drugs, e.g. antibiotics. There are surely still a lot more 
drugs we can copy from nature. 
2. De novo: The big progress in natural sciences makes it today even possible to design 
molecules from scratch. Computer modeling can be used to find out what kinds of 
molecules could have an effect on the target.  
3. High-throughput Screening: This method is mostly used to discover hits which then 
might evolve to lead compounds. A hit is generated by a yes or no question; a lead is a 
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hit which is selected for further studies. The progress in robotics and computational 
power allows testing billions of compounds against the target to check whether any 
compound could be active. After the evaluation of the results some of the tested 
compounds are chosen for further studies.  
4. Biotechnology: Another possibility to find new lead compounds is to genetically 
design living cells which produce disease-fighting biological molecules.  
 
Early Safety Profiling 
Lead compounds are tested with numerous tests to evaluate in an early stage of drug 
development the safety of the possible new drug. Absorption, Distribution, Metabolism, 
Excretion (ADME) and toxicological parameters, in short pharmacokinetics, are evaluated for 
each compound. 
Drugs have to be: 
• absorbed into the blood, 
• distributed to the proper organ, 
• metabolized efficiently and effectively, 
• successfully excreted from the body and 
• shown to be not toxic. 
Pharmacokinetic tests can be performed in living cells or in animals (preferably mouse or rat)  
 
Lead Optimization 
After the screening and the first safety tests lead compounds are modified in different ways to 
find more effective and safer derivatives. Various properties can be changed in the molecule 
to make it more hydrophilic, lipophilic, acidic, basic, etc. The newly generated derivatives are 
tested and out of the test results further changes can be done to step by step develop molecules 
with even better properties. In the end a potential drug candidate is received.  
Already at this point of the drug development the formulation, the delivery mechanism and 
the large-scale production of the new drug should be thought of.  
What kind of inactive substances could be possibly used? 
How should the new drug be assembled to dissolve at the right place and time? 
Is it going to be an oral drug, an injection, an inhalation, etc.? 
Is it possible to produce the new drug in large quantities? 
All these questions should already be answered at this point of the development. 
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Pre-clinical Tests 
In pre-clinical tests the one or more optimized lead compounds are tested more extensively to 
establish whether the drugs are safe to be tested in humans. For this purpose in vitro and in 
vivo tests are performed. In vitro is Latin and means “in glass”. As the name already indicates 
the experiments are performed in test tubes, Petri dishes or beakers. The expression in vivo is 
as well Latin and has the meaning “in life”. The in vivo tests are carried out in living animals. 
The purpose of these experiments is to interpret the mode of action of the drug and its safety. 
To acquire the approval for studies in humans the requirements to a drug candidate are 
extremely high.  
In this phase it is necessary to give again the technological aspects some thoughts as well. The 
production of a larger quantity of the drug for a possible upcoming clinical trial needs to be 
planned precisely. The translation from a smaller to a larger production is not that easily 
performed. If the drug would be approved even another scale up would become necessary.  
At this point already several years have passed and a lot of different studies have been 
performed.  From the originally 5000 to 10000 compounds only one to five molecules are left 
in the development process. Next they are going to be tested in clinical trials. 
 
IND Application 
In US, an Investigational New Drug (IND) application has to be submitted to the United 
States Food and Drug Administration (FDA) before any clinical trial can be started. The 
contents of the application is supposed to contain the results of the preclinical studies, the 
candidate drug’s chemical structure, its mode of action in the body, a list of side effects and 
manufacturing information. Further a detailed plan of the clinical trial explaining how, where 
and by whom the studies will be carried out must be included.  
The major concern of the FDA is the health of the participants of the clinical trial. All 
possible risks have to be ruled out in advance.  
The trial is observed continuously and can be stopped by the FDA or the sponsor company at 
any time if problems occur. In contrast, it is as well possible to stop a trial and put the 
compound immediately to the market, because the drug is acting so well that it would be 
unethical to hold it back from other patients.  
During the ongoing clinical trial the sponsor company is obliged to report regularly to the 
FDA.  
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Clinical Phase I 
In Phase I the drug candidate is tested in healthy volunteers for the first time. Usually 20 to 
100 patients are chosen for this purpose. The focus of the Phase I trial lies on finding out 
whether the drug candidate is safe in humans or not.  
The following questions concerning pharmacokinetics and pharmacodynamics are of interest: 
• How is the drug absorbed, metabolized and eliminated from the body? 
• Are there any side effects? 
• Do we experience all main desirable effects? 
With the help of the answers to these questions it can be determined if the drug candidate 
should be further developed and if yes, what dosing range is safe.  
 
Clinical Phase II 
In the Phase II trial the drug’s effectiveness is tested in around 100 to 500 patients. The 
volunteers suffer from the studied disease. In this phase of the study the short term side effects 
and risks of the drug candidate are tested.  
Further interest in the Phase II lies in the following tasks: 
Is the working mechanism the expected one? 
Does the condition improve? 
What dosage and schedule for drug use is optimal? 
If after all the results still look promising, the much larger Phase III trial needs to be prepared. 
 
Clinical Phase III 
In Phase III the focus lies on generating statistically significant data about safety, efficacy and 
the overall benefit-risk-relationship of the drug. Therefore a much higher number of patients 
is needed (around 1000 to 5000). The most important aspect of this phase is the determination 
if the drug is safe and effective. Additionally the basis for labeling instructions, like 
information on interactions with other medicines, is provided to ensure the right use of the 
drug.  
The Phase III trial is the most expensive and longest phase of all. Numerous different sites 
around the world usually participate in Phase III to ensure a large transverse profile of 
different patients. The management of all sites and the interpretation of their results and data 
is a huge challenge. 
Throughout the Phase III trial other serious issues should be resolved as well. The full scale 
production of the new drug is a critical step and requires to be planned in every detail. 
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However before this can become reality a sophisticated application for FDA approval ought to 
be prepared.  
 
FDA Approval 
As soon as all 3 phases are finished the data is evaluated by the sponsoring company. If the 
data again confirm that the new drug is safe and effective the company submits a New Drug 
Application (NDA) which may consist of 100.000 pages. The FDA has to decide if the drug 
can be approved to the market. The NDA contains all results from the previous years and 
suggestions for manufacturing and labeling of the new drug.  
The application is reviewed by FDA experts who have to decide if the drug is safe and 
effective enough to be approved. Therefore the risk-benefit-ratio is consulted, the package 
insert is checked for every needed information and the methods to produce the drug have to 
guarantee its quality. When all these aspects are positive the FDA approves the drug. In 
contrast, the FDA might request more information before an approval can be given or deny 
the approval right away.  
 
Manufacturing 
The step from small scale to large scale manufacturing is a major undertaking. In many cases 
new manufacturing facilities must be built or old ones reconstructed because the 
manufacturing process varies from drug to drug. The FDA requires from each facility to 
follow the guidelines for Good Manufacturing Practices (GMP).  
 
Ongoing Studies and Phase 4 Trials 
Even after the approval the research on a new drug doesn’t stop. With the larger number of 
patients taking the drug the company is obliged to submit reports regularly, as well as cases of 
adverse drug reactions to the FDA.  
Additionally sometimes further studies are required by the FDA even on an already approved 
drug. They are called Phase IV trials. The purpose of these studies can be the evaluation of 
long term safety or the affects of the drug on a specific subgroup of patients [1-4] [Figure 2].  
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Figure 2 – Scheme of the pharmaceutical research and development process, Figure taken from [3]. 
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B. Biological and Pharmacological 
Background 
 
1. P-glycoprotein 
P-glycoprotein (P-gp) [Figure 3] is a protein in the cell membrane of eukaryotes and 
prokaryotes. P-gp is able to transport a wide variety of substrates against a concentration 
gradient out of the cell using adenosine triphosphate (ATP) as energy supplier which is bound 
and hydrolyzed at the P-gps nucleotide binding domain (NBD). The ATP-dependant efflux 
pump is extensively expressed in the intestinal epithelium, hepatocytes, renal proximal tubular 
cells, adrenal gland, capillary endothelial cells and blood brain barrier.  
 
Figure 3 – Crystallographic structure of the mouse mdr3 protein. 
P-gp belongs to the ABC-transporter family and further to the Multidrug-Resistance-Protein 
subfamily. Therefore it is also called ATP-binding cassette sub-family B member 1 (ABCB1) 
or Multidrug-Resistance-Protein 1 (MDR1).  
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ABC-transporters form a large group of transmembrane proteins that all have an ATP binding 
cassette (ABC) domain in common. They can be divided into three main functional groups: 
importers, exporters and proteins involved in gene expression regulation and DNA repair [5]. 
In prokaryotes importers are responsible for the mediation of nutrients into the cell. They do 
not exist in eukaryotes. Exporters are present in prokaryotes as well as in eukaryotes and 
mediate the efflux of xenobiotic compounds. 
The human genome carries 49 ABC genes, set in seven subfamilies and named A to G [6] as 
shown in Table 1 and Figure 4. ABC-transporters are involved in a large variety of 
physiological processes, consequently they play a role in numerous diseases, e.g. tumor 
resistance, cystic fibrosis, bacterial multidrug resistance and other inherited human diseases as 
well.  
 
Table 1 - Human ABC transporter genes, chromosomal location, number of exons and their functions 
[6] 
Gene Chromosome location Exons Function 
ABCA1 9q31.1 36 Cholesterol efflux onto HDL 
ABCA2 9q34 27 Drug resistance 
ABCA3 16p13.3 26 Multidrug resistance 
ABCA4 1p22 38 N-retinylidene-phosphatidylethanolamine(PE) efflux 
ABCA5 17q24.3 31 Urinary diagnostic marker for prostatic intraepithelial neoplasia (PIN) 
ABCA6 17q24.3 35 Multidrug resistance 
ABCA7 19p13.3 31 Cholesterol efflux 
ABCA8 17q24 31 Transports certain lipophilic drugs 
ABCA9 17q24.2 31 Might play a role in monocyte differentiation and macrophage lipid homeostasis 
ABCA10 17q24 27 Cholesterol-responsive gene 
ABCA12 2q34 37 Has implications for prenatal diagnosis 
ABCA13 7p12.3 36 Inherited disorder affecting the pancreas 
ABCB1 7q21.1 20 Multidrug resistance 
ABCB2 6p21.3 11 Peptide transport 
ABCB3 6p21.3 11 Peptide transport 
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Gene Chromosome location Exons Function 
ABCB4 7q21.1 25 Phosphatidylcholine (PC) transport 
ABCB5 7p15.3 17 Melanogenesis 
ABCB6 2q36 19 Iron transport 
ABCB7 Xq12-q13 14 Fe/S cluster transport 
ABCB8 7q36 15 Intracellular peptide trafficking across membranes 
ABCB9 12q24 12 Located in lysosomes 
ABCB10 1q42.13 13 Export of peptides derived from proteolysis  of inner-membrane proteins 
ABCB11 2q24 26 Bile salt transport 
ABCC1 16p13.1 31 Drug resistance 
ABCC2 10q24 26 Organic anion efflux 
ABCC3 17q22 19 Drug resistance 
ABCC4 13q32 19 Nucleoside transport 
ABCC5 3q27 25 Nucleoside transport 
ABCC6 16p13.1 28 Expressed primarily in liver and kidney 
ABCC7 7q31.2 23 Chloride ion channel (same as CFTR gene  in cystic fibrosis) 
ABCC8 11p15.1 30 Sulfonylurea receptor 
ABCC9 12p12.1 32 Encodes the regulatory SUR2A subunit  of the cardiac K+(ATP) channel 
ABCC10 6p21.1 19 Multidrug resistance 
ABCC11 16q12.1 25 Drug resistance in breast cancer 
ABCC12 16q12.1 25 Multidrug resistance 
ABCC13 21q11.2 6 Encodes a polypeptide of unknown function 
ABCD1 Xq28 9 Very-long-chain fatty acid (VLCFA) transport 
ABCD2 12q11–q12 10 Major modifier locus for clinical diversity  in X-linked ALD (X-ALD) 
ABCD3 1p22–p21 16 Involved in import of fatty acids and/or  fatty acyl-coenzyme As into the peroxisome 
ABCD4 14q24 19 May modify the ALD phenotype 
ABCE1 4q31 14 Oligoadenylate-binding protein 
ABCF1 6p21.33 19 Susceptibility to autoimmune pancreatitis 
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Gene Chromosome location Exons Function 
ABCF2 7q36 14 
Tumour suppression at metastatic sites and  
in endocrine pathway for breast cancer/drug 
resistance 
ABCF3 3q27.1 21 Also present in promastigotes (one of five forms  in the life cycle of trypanosomes) 
ABCG1 21q22.3 13 Cholesterol transport 
ABCG2 4q22 16 Toxicant efflux, drug resistance 
ABCG4 11q23.3 15 Found in macrophage, eye, brain and spleen 
ABCG5 2p21 11 Sterol transport 
ABCG8 2p21 10 Sterol transport 
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Figure 4 – Schematic depiction of the transmembrane domains of ABC subfamilies A to G. 
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In 2009 the mouse P-gp crystal structure was published by Aller et al. [7] revealing up to now 
not known insights: P-gp is comprised of two transmembrane domains (TMDs) and two 
nucleotide binding domains (NBDs) spanning ~136Å perpendicular to and ~70Å in the plane 
of the bilayer. The distance between the NBDs averages ~30Å. The NBD is situated in the 
cytoplasm and responsible for binding and hydrolyzing ATP to provide the energy for the 
efflux process. The TMD consists of two bundles of six alpha helices reaching throughout the 
membrane bilayer: TMs 1 to 3, 6, 10, 11 and TMs 4, 5, 7 to 9, 12. P-gp binds a wide range of 
substrates in this region and changes its conformation to pump substances out of the cell. The 
binding pocket is mostly formed by hydrophobic and aromatic residues. It offers a lot of space 
(internal cavity within the lipid bilayer is ~6000Å3) as it is six times bigger than that of BmrR 
(transcription regulator from Bacillus subtilis) accommodating inter alia lipids, sterols, 
peptides and metabolic products [7] [Figure 5].   
 
Figure 5 – Front and back view of P-gp, Figure taken from [7]. 
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Genes encoding the P-gp are divided into 2 classes in humans (MDR1 and MDR3/MDR2) 
and 3 members in mice (mdr3/mdr1a, mdr1/mdr1b and mdr2) and rats (pgp1, pgp2/mdr1b and 
pgp3) [8] as shown in Table 2. 
Table 2 - Classification of P-gp isoforms [8] 
Species Class I Class II Class III 
Human MDR1  MDR3/MDR2 
Mouse mdr3/mdr1a mdr1/mdr1b mdr2 
Rat pgp1 pgp2/mdr1b pgp3 
 
The sequence conservation of the P-gp gene family across species is very high. Class III is 
more than 90% identical between mice, hamsters and humans. In humans classes I and III are 
75% identical. In mice the highest levels of mdr1 (class II) are described in pregnant uterus, 
adrenals, placenta and kidney, while mdr2 (class III) is mostly expressed in the liver and 
muscle and mdr3 (class I) is frequently detected in the intestine and lung. Moreover, the 
profile of mdr gene expression is conserved across species: human MDR1 (class I) expression 
is overlapping with that of mouse mdr1 and mdr3 and human MDR3 (class III) expression is 
overlapping with mouse mdr2. In rats mdr2 (class III) is highly expressed in the liver, muscle, 
heart and spleen and at lower levels in the lung and brain, whereas mdr1b (class II) is 
frequently detected in the lung and rarely in the liver, kidney, small intestine and spleen[8].  
As mentioned before P-gp is a member of the MDR subfamily and therefore plays a role in 
multidrug resistance. The protein encoded by the MDR gene effluxes xenobiotic compounds 
with broad substrate specificity and as a result decreases drug accumulation in multidrug-
resistant cells. The over expression of P-gp is one reason for the resistance of tumor cells to 
multiple chemotherapeutic drugs [Figure 6]. 
  
19 Introduction 
 
Figure 6 – An illustration of how multidrug resistance inhibitors (MDRIs) can block the P-gp of 
resistant tumor cells, Figure taken from  [9]. 
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C. Computational Background 
1. Molecular Modeling  
All theoretical methods and computational techniques used to model or mimic the behavior of 
molecules are covered by molecular modeling. The techniques are exploited in the fields of 
computational chemistry, computational biology and materials science for exploring 
molecular systems ranging from small chemical systems to large biological molecules and 
material assemblies. The simplest calculations can be executed by hand, but unavoidably 
computers are required to perform molecular modeling of any reasonably sized system. The 
atomistic level description of the molecular systems can be seen as the common feature of 
molecular modeling techniques; individual atoms are the lowest level of information. The 
advantage of molecular modeling is the reduction of the complexity of the system that allows 
considering more atoms during calculations. 
2. Sequence Alignment 
In bioinformatics the sequence alignment is a most widely used tool to analyze DNA, RNA or 
protein similarity. It is routinely a part of more complicated analysis pipelines, like homology 
modeling (see page 25). Alignments are important for highlighting areas of similarity which 
may be associated with specific features that have been more highly conserved than other 
regions [10]. Two methods are known to carry out an alignment: pair wise sequence 
alignment and multiple sequence alignment. The pair wise sequence alignment is used to 
identify regions of similarity that may indicate functional, structural and/or evolutionary 
relationships between two biological sequences. By contrast, the multiple sequence alignment 
aligns three or more biological sequences of similar length. Multiple sequence alignment is an 
important step for phylogenetic analysis, which intends to model the substitutions that have 
happened over evolution and obtain the evolutionary relationships between sequences. 
Several packages are available, e.g. ClustalW, ClustalX, T-Coffee, MAFFT and MUSCLE 
[11].  
a. ClustalW 
ClustalW is a tool to align three or more sequences together in a computationally efficient 
manner. ClustalW multiple sequence alignment is offered for free. The web form [Figure 7] 
is available at http://www.ebi.ac.uk/Tools/msa/clustalw2/.  
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Figure 7 – Depiction of ClustalW web input form, Figure taken from [10]. 
There exist two ways to utilize the service at EBI: interactively or by e-Mail. The interactive 
way displays the results in the browser window. When the e-Mail option is chosen a link to 
the results will be sent by mail. The program accepts nucleic acid or protein sequences in the 
following multiple sequence input format: 
• NBRF/PIR 
• EMBL/UniProt 
• Pearson (FASTA) 
• GDE 
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• ALN/ClustalW 
• GCG/MSF 
• RSF 
For the alignment the sequences can either be pasted into the web form or uploaded to the 
web form in a file. It is very important that each of the sequences has a unique name. If they 
do not, the program will fail. Other reasons for failure are empty lines, white spaces or control 
characters between sequences or at the top of the file. The input for ClustalW is limited to a 
maximum of 500 sequences or to a 1MB file. When the input file or number of sequences is 
too large ClustalW can run for days and in some cases may not finish at all. For larger 
amounts of data the e-Mail results option should be used. The alignment method can be set to 
slow but accurate, or fast but approximate. ClustalW produces several outputs depending on 
the selected options when submitting the job. The output format for the alignment file can be 
as follows: 
• ALN/ClustalW with base/residue numbering 
• ALN/ClustalW without base/residue numbering 
• GCG MSF 
• PHYLIP 
• NEXUS 
• NBRF/PIR 
• GDE 
• Pearson/FASTA 
By default the main output is the alignment file [Figure 8]. Other outputs can be downloaded 
in the results summary tab. The ClustalW output contains a Scores Table that shows the pair 
wise scores calculated for every pair of sequences that is to be aligned. Pair wise scores are 
the number of identities between the two sequences, divided by the length of the alignment, 
and represented as a percentage. This alignment is only a forerunner to the full multiple 
alignment [10]. 
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Figure 8 – A sequence alignment of two human zinc finger proteins, calculated by ClustalW and 
identified on the left by Gen Bank accession number. An * (asterisk) indicates positions which have a 
single, fully conserved residue. A : (colon) indicates conservation between groups of strongly similar 
properties (same color group). A . (period) indicates conservation between groups of weakly similar 
properties (similar shapes), edited from  [10]. 
The residue colors according to their physicochemical properties: 
Residue Color Property 
AVFPMILW RED Small (small+ hydrophobic (incl.aromatic -Y)) 
DE BLUE Acidic 
RK MAGENTA Basic - H 
STYHCNGQ GREEN Hydroxyl + sulfhydryl + amine + G 
Others Grey Unusual amino/imino acids etc 
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3. Homology Modeling 
 
 
Figure 9 – Basic concept of Homology Modeling. For an unknown target structure with a known 
protein target sequence a homologous structural resolved protein is searched via sequence alignment. 
This protein is then served as a structural template for the target sequence, Figure taken from [12]. 
 
With the techniques’ development in molecular biology rapid identification, isolation and 
sequencing of genes became possible and enabled to infer the sequences of many proteins. A 
major goal of structural biology is the prediction of the three-dimensional structure from the 
sequence. Unfortunately this aim hasn’t been reached until now. Nevertheless, alternative 
strategies allow developing models of protein structure when the X-ray or NMR structure is 
not available.  
One method to calculate reasonable models of protein structures is homology modeling. This 
approach uses a “target” protein from its amino acid sequence and an experimental three-
dimensional structure of a related homologous “template” protein for model building [Figure 
9]. Homology modeling is based on the identification of one or more known protein structures 
resembling the structure of the query sequence and on the calculation of an alignment 
mapping residues in the query sequence to residues in the template sequence [Figure 10].  
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Figure 10 – Scheme of Homology modeling in more detail, Figure taken from [13]. 
1. Search for homologous sequences 
2. Search for homologous sequences with known 3D structure 
3. Cleaning the PDB files for the subsequent steps 
4. Determine sequence alignments between target and templates  
5. Finally building the structural models based on aligned sequence and structural template 
 
The sequence alignment and template structure are responsible for the quality of the 
homology model. Alignment gaps complicate the calculation and decrease the quality because 
they indicate that a structural region is present in the target but not in the template. 
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Accordingly model quality declines with decreasing sequence identity: high-accuracy 
comparative models are based on more than 50% sequence identity to their templates, 
medium-accuracy models on 30-50% identity and finally low-accuracy models on less than 
30% sequence identity [14].  
a. Modeller 
Modeller is a computer program that calculates three-dimensional structures of proteins and 
their assemblies by satisfaction of spatial restraints. It is most commonly utilized for 
homology or comparative protein structure modeling. The program works with a scripting 
language and does not include any graphics. It will run on Windows, Mac or UNIX. For the 
calculation an alignment of an amino acid sequence that has to be modeled and a known 
related structure is needed [Figure 11]. 
 
 
>P1;3g5u_pajeva.pdb 
structureX:3g5u_pajeva.pdb:   33:B : 1271 :B :::3.80:0.347 
VSVLTMFRYAGWLDRLYML 
VGTLAAIIHGVALPLMMLIFGDMTDSFASVGN--VSKNSTNMSEADKRAM 
FAK--LEEEMTTYAYYYTGIGAGVLIVAYIQVSFWCLAAGRQIHKIRQKF 
FHAIMNQEIGWFDVHDVGELNTRLTDDVSKINEGIGDKIGMFFQAMATFF 
GGFIIGFTRGWKLTLVILAISPVLGLSAGIWAKILSSFTDKELHAYAKAG 
AVAEEVLAAIRTVIAFGGQKKELERYNNNLEEAKRLGIKKAITANISMGA 
AFLLIYASYALAFWYGTSLVISKEYSIGQVLTVFFSVLIGAFSVGQASPN 
IEAFANARGAAYEVFKIIDNKPSIDSFSKSGHKPDNIQGNLEFKNIHFSY 
PSRKEVQILKGLNLKVKSGQTVALVGNSGCGKSTTVQLMQRLYDPLDGMV 
SIDGQDIRTINVRYLREIIGVVSQEPVLFATTIAENIRYGREDVTMDEIE 
KAVKEANAYDFIMKLPHQFDTLVGERGAQLSGGQKQRIAIARALVRNPKI 
LLLDEATSALDTESEAVVQAALDKAREGRTTIVIAHRLSTVRNADVIAGF 
DGGVIVEQGNHDELMREKGIYFKLVMTQT 
LDEDVPPASFWRILK 
LNSTEWPYFVVGIFCAIINGGLQPAFSVIFSKVVGVFTNGGPPETQRQNS 
NLFSLLFLILGIISFITFFLQGFTFGKAGEILTKRLRYMVFKSMLRQDVS 
WFDDPKNTTGALTTRLANDAAQVKGATGSRLAVIFQNIANLGTGIIIS-- 
LIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA 
IENFRTVVSLTREQKFETMYAQSLQIPYRNAMKKAHVFGITFSFTQAMMY 
FSYAAAFRFGAYLVTQQLMTFENVLLVFSAIVFGAMAVGQVSSFAPDYAK 
ATVSASHIIRIIEKTPEIDSYSTQGLKPNMLEGNVQFSGVVFNYPTRPSI 
PVLQGLSLEVKKGQTLALVGSSGCGKSTVVQLLERFYDPMAGSVFLDGKE 
IKQLNVQWLRAQLGIVSQEPILFDCSIAENIAYGDNSRVVSYEEIVRAAK 
EANIHQFIDSLPDKYNTRVGDKGTQLSGGQKQRIAIARALVRQPHILLLD 
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVIQNGK 
VKEHGTHQQLLAQKGIYFSMVSVQA--- 
* 
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>P1;MDR1_RAT 
sequence:MDR1_RAT:    : :    : :::: 
VGIFGMFRYADWLDKLCMA 
LGTLAAIIHGTLLPLLMLVFGYMTDSFTPSRDPHSDRAITNQSEINSTHT 
VSDTSLEEDMAMYAYYYTGIGAGVLIVAYIQVSLWCLAAGRQIHKIRQKF 
FHAIMNQEIGWFDVNDAGELNTRLTDDVSKINDGIGDKLGMFFQSITTFS 
AGFIIGFISGWKLTLVILAVSPLIGLSSAMWAKVLTSFTNKELQAYAKAG 
AVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRVGIKKAITANISIGI 
AYLLVYASYALAFWYGTSLVLSNEYSIGQVLTVFFSILLGTFSIGHLAPN 
IEAFANARGAAYEIFKIIDNEPSIDSFSTKGHKPDSIMGNLEFKNVYFNY 
PSRSEVKILKGLNLKVKSGQTVALVGNSGCGKSTTVQLLQRLYDPIEGEV 
SIDGQDIRTINVRYLREIIGVVSQEPVLFATTIAENIRYGRENVTMDEIE 
KAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIAIARALVRNPKI 
LLLDEATSALDTESEAVVQAALDKAREGRTTIVIAHRLSTVRNADVIAGF 
DGGVIVEQGNHEELMKEKGIYFKLVMTQT/ 
VDEDVPMVSFWQILK 
LNISEWPYLVVGVLCAVINGCIQPVFAIVFSKIVGVFSRDDDHETKQRNC 
NLFSLLFLVMGMISFVTYFFQGFTFGKAGEILTKRLRYMVFKSMLRQDIS 
WFDDHKNTTGSLTTRLASDASNVKGAMGSRLAVVTQNVANLGTGIILSLV 
LVYGWQLTLLLVVIIPLIVLGGIIEMKLLSGQALKDKKELEISGKIATEA 
IENFRTVVSLTREQKFETMYAQSLQIPYRNALKKAHVFGITFAFTQAMIY 
FSYAACFRFGAYLVARELMTFENVMLVFSAVVFGAMAAGNTSSFAPDYAK 
AKVSASHIIGIIEKIPEIDSYSTEGLKPNWLEGNVKFNGVKFNYPTRPNI 
PVLQGLSFEVKKGQTLRLVGSSGCGKSTVVQLLERFYNPMAGTVFLDGKE 
IKQLNVQCVRA-LGIVSQEPILFDCSIAENIAYGDNSRVVSHEEIVRAAR 
EANIHQFIDSLPEKYNTRVGDKGTQLSGGQKQRIAIARALVRQPHILLLD 
EATSALDTESEKVVQEALDKAREGRTCVVIAHRLSTIQNADLIVVIQNGQ 
VKEHGTHQQLLAQKGIYFSMVQAGAKRS 
* 
Figure 11 – Depiction of an aligned sequence in pir format. The template sequence (PDB entry 
3G5U) is given in the first part. The second part shows the alignment of the template sequence 
(MDR1_RAT). The * symbols sign the end of each sequence.  
 
With the command “mod9.10 model-default.py” Modeller automatically calculates a model 
with all non-hydrogen atoms.  
“First many distance and dihedral angle restraints on the target sequence are calculated from 
its alignment with template 3D structures. The form of these restraints was obtained from a 
statistical analysis of the relationships between many pairs of homologous structures. This 
analysis relied on a database of 105 family alignments that included 416 proteins with known 
3D structure. By scanning the database, tables quantifying various correlations were obtained, 
such as the correlations between two equivalent Cα-Cα distances or between equivalent main 
chain dihedral angles from two related proteins. These relationships were expressed as 
conditional probability density functions (pdf) and can be used directly as spatial restraints. 
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Next, the spatial restraints and CHARMM energy terms enforcing proper stereochemistry are 
combined into and objective function. Finally, the model is obtained by optimizing the 
objective function in Cartesian space. The optimization is carried out by the use of the 
variable target function method employing methods of conjugate gradients and molecular 
dynamics with simulated annealing. Several slightly different models can be calculated by 
varying the initial structure. The variability among these models can be used to estimate the 
errors in the corresponding regions of the fold [15] [Figure 12].”  
 
Figure 12 – Scheme of building a homology model within MODELLER. 1. The known template 3D 
structure is aligned with the target sequence to be modeled. 2. Spatial features, as Cα-Cα distances, 
hydrogen bonds and main chain/side chain dihedral angles are extracted from the template and 
transferred to the target. 3. The 3D model is obtained by satisfying all the restraints as good as 
possible, taken from [15]. 
 
For evaluation Modeller offers the molecular PDF (molpdf), which is the sum of all restraints, 
the GA-341 score, which assesses the overall fold quality and the “discrete optimized energy” 
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score (DOPE). The molpdf and DOPE score are not absolute measures therefore they can only 
be utilized to rank models. Molpdf is specific for a set of restraints and DOPE for a target 
sequence. The molpdf and the DOPE score should be as low as possible and the GA341 score 
ranges from 0 (worst) to 1 (native like). However, the GA341 score is not as good as the 
DOPE score at distinguishing well from bad models [15].  
Additionally, Modeller is able to perform multiple comparisons of protein sequences or 
structures, clustering of proteins and searching of sequence databases.  
 
4. Docking 
Docking calculations have been used in pharmaceutical research for nearly two decades. 
Virtual screening on protein templates, which varies from molecular similarity- and ligand-
based virtual screening methods, offers an opportunity for the de novo identification of active 
compounds, without favoritism towards known hits or leads. 
In the field of molecular modeling, docking appears as a computational simulation which 
foresees the preferred orientation of a molecule to a second one when bound to each other 
[16]. More precisely the docking process involves the prediction of ligand conformation and 
orientation within a targeted binding site and the prediction of the binding affinity [17].  
Most of the computer studies on molecular docking assume one of the docking partners to be 
a protein, also called “receptor” or “receiving molecule”. On the other hand there is the 
complementary partner molecule which binds to the receptor, named “ligand”. During the 
first step posing samples the ligands’ translational, rotational and conformational degrees of 
freedom within the active site (see a, page 31). After this calculation, different poses or 
binding modes can be evaluated with the scoring function (see b, page 32), which counts the 
number of favorable intermolecular interactions such as hydrogen bonds and hydrophobic 
contacts. In the end the ranking classifies which ligands most likely interact favorably with a 
particular receptor based on the assigned scoring values.  
The problem with molecular docking can be seen as a “lock and key” issue. In this case the 
protein is represented by the “lock” and the ligand by a “key”. During the docking calculation 
the protein and the ligand alter their conformation to achieve the “best fit” orientation, also 
known as “induced fit”. 
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a. Posing 
In this initial step searching algorithms sample ligand orientations within the binding site. 
Most docking programs consider the protein as rigid and ligand flexibility is treated mainly by 
three categories [17]: 
1. Simulation methods (molecular dynamics, energy minimization) 
2. Random or stochastic methods (Monte Carlo, genetic algorithms, tabu search) 
3. Systematic methods (incremental construction, conformational search, databases) 
1. Simulation methods are implemented in the following software packages 
• DOCK 
• Glide 
• MOE-Dock 
• AutoDock 
• Hammerhead 
2. Random or stochastic methods are implemented in the following software packages 
• AutoDock (MC) 
• MOE-Dock (MC,TS) 
• GOLD (GA) 
• PRO_LEADS (TS) 
3. Systematic methods are implemented in the following software packages 
• DOCK (incremental) 
• FlexX (incremental) 
• Glide (incremental) 
• Hammerhead (incremental) 
• FLOG (database) 
 
The handling of protein flexibility is less advanced than that of ligand flexibility, but various 
approaches have been utilized to flexibly calculate at least part of the target, including 
molecular dynamics and Monte Carlo calculations, rotamer libraries and protein ensemble 
grids [17].  
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b. Scoring 
After the posing the fit complementarity of the generated ligand-receptor complexes is 
evaluated by a scoring function. This function attempts to estimate the binding free energy of 
the complex with computational algorithms which sums up calculated ligand-receptor 
interactions. Scoring functions implemented in docking programs make various assumptions 
and simplifications in the evaluation of modeled complexes and do not fully account for a 
number of physical phenomena that determine molecular recognition, e.g. entropic effects. 
Basically three different types of scoring functions can be distinguished [17]: 
Types of scoring functions: 
1. Force-field-based 
• D-Score 
• G-Score 
• GOLD 
• AutoDock 
• DOCK 
2. Empirical 
• LUDI 
• F-Score 
• ChemScore 
• SCORE 
• Fresno 
• X-Score 
3. Knowledge-based 
• PMF 
• DrugScore 
• SMoG 
c. GOLD 
GOLD is a program which calculates the docking modes of small molecules in protein 
binding sites. It is offered as a part of the program GOLD Suite, also containing Hermes for 
structure visualization and manipulation, and GOLDMine for post-processing of docking 
results. As mentioned on page 31 GOLD uses a genetic algorithm (GA) for protein-ligand 
docking. A GA is a computer program that imitates the process of evolution [18]. “It sets up a 
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population of potential solutions at random. Each member of the population is encoded as a 
chromosome, which contains information about the mapping of protein ligand interactions. 
Every chromosome is assigned a fitness score based on its predicted binding affinity and the 
chromosomes within the population are ranked according to fitness [19].”  
The ligand can be kept fully flexible, the protein partially flexible or it is possible to dock into 
multiple models of the same or different proteins. GOLD accepts mol2, mol and pdb as ligand 
input files and pdb and mol2 as protein file formats. The docking run can be launched with 
the help of the set-up wizard via Hermes. Before the calculation can be started the following 
preparations have to be done: 
• GA speed settings 
• loading the protein target 
• specifying the binding site 
• uploading the ligand(s) 
• selecting the number of dockings and early termination allowance 
• choosing the fitness function 
GOLD provides three different scoring functions: GOLDScore, ChemScore and ASP. All of 
them calculate fitness scores that are dimensionless. The score illustrates how good the pose 
is; the higher the score, the better the docking result. The GOLDScore fitness function is the 
original scoring function offered with GOLD and is the one selected by default. It has been 
developed for the prediction of ligand binding positions and takes into consideration factors 
such as H-bonding energy, van der Waals energy and ligand torsion strain [19].  
GOLD Fitness = Shb_ext + Svdw_ext + Shb_int + Svdw_int 
Shb_ext: protein-ligand hydrogen-bond score 
Svdw_ext: protein-ligand van der Waals score 
Shb_int: contribution to the Fitness due to intramolecular hydrogen bonds in the ligand 
Svdw_int: contribution due to intramolecular strain in the ligand [20] 
The ChemScore fitness function assesses the total free energy change that occurs on ligand 
binding and was trained by regression against binding affinity data. The ASP fitness function 
is an atom-atom potential obtained from a database of protein-ligand complexes and can be 
likened to other such scoring potentials, e.g. PMF and Drugscore. ASP integrates some 
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ChemScore terms. As the fitness scores are dimensionless they cannot be utilized explicitly as 
values for binding energy or binding affinity [19]. 
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II. Aim of the study 
 
In early stage drug development the pharmacokinetic profile and the possible toxicity of a 
drug candidate are determined in animal models (usually mouse or rat) before it is tested in 
human beings. Thus predicting toxicity only in humans during the clinical trials is far too late.  
First pharmacokinetic and toxicological tests are carried out in animals several years before 
the drug candidate is even admitted for testing in humans. Thus, besides developing predictive 
in silico models for the identification of ligands for human P-gp it is also important to 
establish predictive models for mouse and rat P-gp. Furthermore, early in silico prediction of 
in vivo toxicological outcomes might increase the quality of drug candidates, lower the 
attrition rate during subsequent phases of drug development, and reduce the number of 
animals to be used in preclinical studies.  
 
The difficulty in structure-based in silico studies with membrane proteins like P-gp is the fact 
that due to technical difficulties in the crystallizing process, X-ray structures and other high-
resolution structural data are mostly unavailable. Therefore, computational methods such as 
homology modeling and docking are needed to explore molecular binding modes. However, 
in case of P-gp, since 2009 the mouse crystal structure is available [7]. As the rat P-gp shares 
high sequence identity (92%) to the recent crystallized mouse P-gp, we used it as a template 
for a rat P-gp homology model. 
 
The obtained protein homology model will be validated using routine methods. Subsequently, 
the model will be used for docking of known rat P-gp inhibitors into the rat P-gp homology 
model. The resulting docking ranking list will then be compared to the known IC50 values of 
these already published and tested inhibitors. Hence this comparison will be used to evaluate 
the predictive potency of the model.  
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III. Materials and Methods 
 
A. Multiple sequence alignment 
The P-gp sequences of different species (dog, frog, hamster, human, mouse, rabbit, rat and 
sheep) were compared with ClustalW version 2.1 [21, 22] taking the whole protein as well as 
the transmembrane domains only. All settings were used as default. Figure 13 shows the 
alignment of the whole P-gp sequences. 
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Figure 13 – P-gp Sequence alignment between different species: dog, frog, hamster, human, mouse, 
rabbit, rat and sheep. An * (asterisk) indicates positions which have a single, fully conserved residue. 
A : (colon) indicates conservation between groups of strongly similar properties (same color group). 
A . (period) indicates conservation between groups of weakly similar properties (similar shapes) [10]. 
The residue colors according to their physicochemical properties: 
Residue Color Property 
AVFPMILW RED Small (small+ hydrophobic (incl.aromatic -Y)) 
DE BLUE Acidic 
RK MAGENTA Basic - H 
STYHCNGQ GREEN Hydroxyl + sulfhydryl + amine + G 
Others Grey Unusual amino/imino acids etc 
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B. Sequence Alignment and Variability 
For the purpose of sequence alignment and variability calculations tools from the 
Bioinformatics Resource Portal ExPASy were used [23]. With ClustalW version 2.1 a 
sequence alignment between different species considering the whole sequences as well as the 
transmembrane domains only was calculated. The assignment of the transmembrane regions 
for  P-gp were taken from UniProt [24]. Further the variability of the aligned animal 
sequences and the mouse P-gp structure was checked with the Protein Variability Server 
(PVS) [25]. For all calculations the settings were used as default. 
C. Homology Model 
For the homology model the mouse P-gp structure (PDB ID: 3G5U, resolution: 3,8Å [7]) was 
taken as the template and the rat P-gp sequence was defined as the target. A sequence 
alignment was performed with ClustalW version 2.1. The resulting alignment was identical to 
the multiple sequence alignment mentioned above and used for model building with 
MODELLER version 9.8 [26]. All settings were kept as default. To adjust the disruption in 
TM helix 12 (residues 982-1000), this part was replaced by the homologous part of TM helix 
6 (residues 339-357) according to Pajeva et al. [27]. To analyze the quality of the model the 
outliers were checked in MOE [28] and with PROCHECK [29, 30]. From the 100 generated 
models, the final one was chosen regarding the generously allowed and disallowed outliers, 
the DOPE score, Z-score, QMEAN and dfire-energy, all calculated with SWISS-MODEL [31, 
32].  
D. Database Search 
The search for rat P-gp ligands was carried out  in the Transporter Database TP search [33], in 
the  ChEMBL database (ChEMBLdb) [34], and in PubMed [35]. 
E. Docking 
For the docking study 6 rat P-gp inhibitors with known IC50 values were chosen [36]. 
Minimization and protonation of the ligands as well as the correct determination of 
ASN/GLN/HIS flips for the protein was performed with MOE. For the docking process 
GOLD Suite version 5.1 was utilized [19, 20]. With GOLD, hydrogens were added, the 
binding site was defined as the entire TM region and all side chains were kept rigid. For the 
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calculation 100 genetic algorithm runs per molecule were performed and the scoring function 
GOLDScore as in GOLD implemented was used to evaluate the received complexes. 
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IV. Results and Discussion 
 
A. Sequence Alignment 
For the multiple sequence alignment the P-gp sequences of dog, frog, hamster, human, mouse, 
rabbit, rat and sheep were considered. The alignment was calculated twice with ClusalW: first 
the whole P-gp sequence was utilized and second only the transmembrane domains (TMDs) 
as described within UniProt were taken for the calculation. The results were not surprising: 
Tables 3 and 4 show that the sequence similarities are very high among these species, 
especially between mouse and rat (92% or rather 88%). The little differences in percentages 
involving the whole sequence and the transmembrane domains only are expected, as the 
nucleotide binding domain is strongly conserved and thus the whole protein comparison 
shows slightly higher values than the TMD only.  
 
Table 3 – Results of the multiple sequence alignment of the whole P-gp sequences, shown in percent 
species dog frog hamster human mouse rabbit rat sheep 
dog 100 66 87 90 80 85 79 87 
frog   100 68 67 63 66 63 65 
hamster     100 87 82 85 82 84 
human       100 80 86 79 87 
mouse         100 78 92 78 
rabbit           100 77 83 
rat             100 77 
sheep               100 
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Table 4 – Results of the multiple sequence alignment of the P-gp transmembrane domains, shown in 
percent 
species dog frog hamster human mouse rabbit rat sheep 
dog 100 60 84 88 75 82 74 87 
frog 
 
100 59 62 57 58 58 60 
hamster 
  
100 84 77 82 76 82 
human 
   
100 77 85 76 86 
mouse 
    
100 73 88 75 
rabbit 
     
100 73 83 
rat 
      
100 74 
sheep 
       
100 
 
 
B. Sequence Variability 
Further the variability of the aligned animal P-gp sequences and the mouse P-gp structure was 
checked with the Protein Variability Server (PVS). Figure 14 shows that the variability is 
higher in the beginning than at the end of the P-gp sequence. In contrast in the transmembrane 
regions in the middle of the sequence it is low or even not existing. For a better imagination 
Figure 15 illustrates the conservation color-coded: blue represents conserved regions and red 
variable ones. Again the very high sequence conservation is demonstrated. 
 
 
Figure 14 – Diagram showing the variability; the higher the red peak, the higher the variability of the 
amino acids. 
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Figure 15 – Colored P-gp illustrates the conservation; blue represents conserved regions, red 
variable ones. 
 
C. Homology Model 
The publications of the mouse P-gp structure [7], the human P-gp homology model [37], and 
the alignment results described earlier paved the way for  developing a rat P-gp model. The 
rat homology model was based on the structure of mouse P-gp (PDB ID: 3G5U) and its 
alignment to the rat P-gp sequence (sequence similarity: 92%). With these inputs the 
modeling program MODELLER [26] generated 100 different homology models which were 
subsequently refined due to the bad molpdf values (10401-11979). The deletion of a loop did 
only slightly improve the score. The low score was mainly due to a disruption in TM helix 12 
[Figure 16]. This could be remarkably improved when following the procedure from  Pajeva 
et al., by exchanging it with TM helix 6 (residues 339-357) [27].  
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Figure 16 – Depiction of the disruption in TM helix 12 (yellow) and TM helix 6 (green). 
 
The molpdf decreased substantially after this exchange, now ranging from 7462 to 7873, as 
shown in Table 5.  
 
 
 
Table 5 – MODELLER scores before (above) and after (below) the exchange of the TM helix 12. The 
molpdf decreased substantially after exchanging the helices. 
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The resulting models were evaluated with the geometry check tool implemented in MOE [28]. 
All models were assessed with the highest possible GA341 score of 1. Additionally, the 
models were analyzed with PROCHECK [29, 30] and according to the obtained results the six 
best models (model number 77, 95, 60, 52, 21 and 54) were chosen for further validation with 
SWISS-MODEL [31, 32].  These tests showed in average a DOPE of -123286, a Z-Score of   
-401, a QMEAN of 0.4, a dfire-energy of -1513.34 and a disallowed outliers score of 0.82 
[Table 6]. 
 
 
Table 6 – Results of the model analysis with PROCKECK and SWISS-MDOEL.  
NR. DOPEa disallowedb Z-Scorec QMEANd dfire-energye 
77 -125664,4219 0,9000 -3,997 0,402 -1523,43 
95 -124369,2734 0,8000 -4,018 0,4 -1502,16 
60 -125507,2891 0,9000 -4,134 0,389 -1515,94 
52 -125562,9141 0,8000 -4,064 0,395 -1517,53 
21 -125046,2656 0,7000 -3,861 0,414 -1511,35 
54 -125562,9141 0,8000 -4,003 0,401 -1509,63 
a discrete optimized energy,  
b disallowed outliers in the Ramachandran plot,  
c measure for the absolute quality of the model,  
d score of the whole model reflecting the predicted model reliability ranging from 0 to1,  
e assessment of non bonded atomic interactions [31] 
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As a result of this analysis, model number 21 was chosen as the best model with a DOPE of -
125046, a disallowed outliers score of 0.7, a Z-Score of -3.86, a QMEAN of 0.41 and a dfire-
energy of -1511 [Figure 17]. 
 
Figure 17 – Depiction of the rat P-gp model number 21. 
 
Subsequently, the models were color coded according to their similarities and differences in 
the amino acid sequence. Figure 18 shows that not only as already mentioned before the 
sequence similarity between species is high but also the sequence identity. 
 
 
Figure 18 – Comparison of the human, mouse and rat P-gps, pink demonstrate identical amino acids, 
black shows different amino acids, (a) human and mouse P-gp, (b) human and rat P-gp, (c) mouse and 
rat P-gp. 
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D. Database search 
In a next step we focused on the search for substrates and inhibitors of the human, mouse and 
rat P-gps. Especially rat P-gp ligands were of interest in order to carry out docking studies. 
For this purpose two databases were consulted: the Transport Database [33] and the ChEMBL 
database (ChEMBLdb) [34].  
Surprisingly, this task turned out to be a tricky undertaking, as no rat P-gp ligands were found 
in these databases. On the other hand, numerous human and mouse P-gp substrates and 
inhibitors were found twice, threefold, etc. in one database, which made data collection very 
elaborative and time consuming. Nevertheless, in the end it was possible to filter out the 
requested information.  
1. Transporter Database 
In the Transporter Database only human substrates and inhibitors and mouse substrates were 
found. There was no information for the rat at all. 256 human substrates and 12 mouse 
substrates were detected, whereupon all 12 mouse substrates overlap with the human 
substrates. On the other hand, only 371 human but no mouse or rat inhibitors were retrieved 
[Figure 19 and 20].  
 
Figure 19 – Venn diagrams of the P-gp ligands found in the TP-database [33]. 
  
52 Results and Discussion 
 
Figure 20 – Overlapping 12 human and mouse substrates retrieved by Tp-search [33]. 
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2. ChEMBL Database 
The ChEMBLdb [34] is not sub classified into substrates and inhibitors like the TP search 
database. One can only find ligands which are described more precisely in their profile. 
During the request once again only human and mouse ligands, but not a single rat ligand was 
returned [Figure 21 and 22]. In total 1087 human and 110 mouse ligands were detected, with 
33 overlapping ones.  
 
Figure 21 – Venn diagram of the P-gp ligands detected in the ChEMBLdb [34] for different species. 
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Figure 22 – Overlapping 33 human and mouse compounds of the ChEMBL search[34]. 
 
3. PubMed 
Having not found any rat data in the main public available  databases, in the next step a 
literature search in PubMed [35] was conducted. A few articles were detected leading to in 
total 18 substrates and inhibitors of  rat P-gp [Figure 23] [36, 38-43]. 
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Figure 23 – Resulting 18 rat P-gp ligands returned from PubMed [35]. 
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E. Docking 
 
 
Figure 24 – Binding site of the P-gp marked in purple.  
 
The docking software GOLD [19, 20] was used to dock 6 rat P-gp inhibitors [36] (taken from 
PubMed search) with known IC50 values against the rat homology model. The minimization 
and protonation of the ligands as well as the correct determination of ASN/GLN/HIS flips for 
the protein was performed with MOE [28]. According to Klepsch et al. [37] there is evidence 
that the proteins pore is filled with water and therefore it was suggested to dock the ligands in 
their ionized state. Before the docking run hydrogens were added to the protein using GOLD 
and the binding site was defined as the entire TM region [Figure 24]. During docking all side 
chains were kept rigid. GOLD is based on a genetic algorithm and for each of the 6 ligands 
100 docking poses were calculated. Subsequently, the scoring function GOLDScore 
implemented in GOLD was used to rank the complexes.  
The obtained poses were located in the whole TM region,showing  interactions with residues 
of different TM helices. The analysis of the complexes showed that especially TM helices 1, 
5, 6 and 12 were involved in interactions. Frequently, interactions were observed with 
residues F70 located in TM helix 1 and F335 in TM helix 6. Also residue T306 was involved 
in some interactions, whose human analogue T307 was shown to be important in ligand 
interactions [Figure 25] [37]. 
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Figure 25 – 2D ligand interaction 
plot of the best scored pose 
according to GOLDScore for each of 
the 6 P-gp ligands, docked into the 
rat P-gp homology model. 
(a) Elacridar pose 
(b) Quinine pose 
(c) Quinidine pose 
(d)  Ketoconazole pose 
(e) Itraconazole pose 
(f) Verapamil pose 
(a) 
(b) 
(c) 
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(d) 
(e) 
(f) 
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A representative docking pose is depicted in Figure 26 showing the best ranked Chinine 
receptor complex. 
 
Figure 26 – Best scored Chinine pose according to GOLDScore. 
 
Finally, the docking results were compared with the experimental IC50 values from Zolnerciks 
et al. [36]. The docking ranks were obtained according to the Fitness scores from the 
“bestranking” file produced by GOLD. Surprisingly, the experimental and docking ranks were 
almost identical disregarding only ranks 3 and 4 which were switched [Table 7].   
 
Table 7 – Comparison of rankings according to experimental data  
and GOLD scoring 
Inhibitor Rank (exper) Rank (dock) 
Elacridar 1 1 
Quinine 6 6 
Quinidine 5 5 
Ketoconazole 4 3 
Itraconazole 2 2 
Verapamil 3 4 
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V. Summary and Outlook 
 
In general the drug development workflow can be divided into 3 main stages: drug discovery, 
preclinical stage (animal in vivo trials) and clinical stage (human in vivo trials). Especially in 
the early drug discovery stage in silico predictions are widely applied. One important field of 
in silico activity is the generation of reliable models for ADME and toxicity profiles. Here P-
gp plays a key role because of its biological function as a xenobiotic carrier between 
distribution compartments.  
Nowadays a huge amount of experimental data against human P-gp is already available and 
has been implemented in the generation of prediction models during the drug discovery stage. 
However, in the early preclinical phase of animal in vivo studies, the animal P-gp activity 
profile may differ significantly and may lead to attrition. Thus next to existing in silico 
predictive models against human P-gp activity, predictive in silico models against rat and 
mouse would be beneficial.  
In our study we tackled this by the generation of a structure based rat P-gp prediction tool.  
Due to the lack of a crystal structure of  rat P-gp, homology modeling and computational 
ligand docking represent the only possibilities for structure-based hypotheses for protein-
ligand-interactions. Therefore, the accurate prediction of membrane protein structures and 
their interaction with small molecules stays a challenge.  
With our work we tried to take the first step towards in silico ADME and toxicity predictions 
with a focus on the role of P-gp. This would allow to assess potential failure of a drug 
candidate at an early stage in the drug development pipeline. For this reason we first 
constructed a homology model of  rat P-gp. Then we compiled a ligand library composed of 
known rat P-gp ligands from literature. A subset of this  library was then docked into the 
homology model and the subsequent ranking list was compared to the experimental (IC50) 
rankings.  
The resulted ranking list was promising: the docking was able to correctly assign almost all 
ranks, only ranks 3 and 4 were switched. Of course additional validation needs to be done, but 
the obtained results in this study assume its suitability for structure-based prediction models. 
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However, we have to consider that the amount of the docked compounds for validation was 
limited. For a more sophisticated validation more experimental data on compounds from 
industry is needed.  
Next to the predictive capabilities, the structural insights of the complexes can as well 
ameliorate our undertanding and hypothesis of inhibitor binding on a molecular level, 
stimulating scientists to conduct new experiments.  
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List of abbreviations 
ABC    ATP Binding Cassette 
ADME   Absorption, Distribution, Metabolism and Excretion 
ATP    Adenosine Triphosphate 
ChEMBLdb   ChEMBL Database 
DNA    Desoxyribonucleotide Acid 
DOPE    Discrete Optimized Energy 
EBI    European Bioinformatics Institute 
FDA    Food and Drug Administration in the USA 
GA    Genetic Algorithm 
GMP    Good Manufacturing Practice 
IC50   Half Maximal Inhibitory Concentration 
IND    Investigational New Drug 
MDR    Multidrug Resistance 
Molpdf  Molecular PDF 
NBD    Nucleotide Binding Domain 
NDA    New Drug Application 
PDB   Protein Database 
P-gp    P-Glycoprotein 
PVS    Protein Variability Server 
RNA    Ribonucletide Acid 
TAP   Antigen Peptide Transporter 
TM    Transmembrane 
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